C. Ola Landgren, Leader of Translational & Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared on LinkedIn:
“Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered programs for spotting the signs of cancer. The deal includes Tempus paying out Paige’s remaining commitment to Microsoft Azure for its cloud-computing services.
Tempus set its eyes on Paige for its massive, anonymized dataset, which encompasses nearly 7 million digitized pathology slides and clinical data licensed from Memorial Sloan Kettering Cancer Center.”
More posts featuring C. Ola Landgren.